SCHEMBL10165976

SCHEMBL10165976

Cc1ccc(Nc2ccc(N3CCN(C)CC3)cc2)c2nccn12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA2A P08913 3/20 0.51
ADRA2C P18825 3/20 0.51
ADRA2B P18089 2/20 0.51
MAPKAPK5 Q8IW41 1/20 0.48
MAPKAPK2 P49137 8/20 0.47
RAD52 P43351 2/20 0.47
GFER P55789 1/20 0.47
CCNK O75909 1/20 0.44
CCNA2 P20248 1/20 0.44
CDK2 P24941 1/20 0.44
CCND3 P30281 1/20 0.44
CDK9 P50750 1/20 0.44
CDK6 Q00534 1/20 0.44
AURKA O14965 1/20 0.44
CDK4 P11802 1/20 0.44
EGFR P00533 2/20 0.44
JAK2 O60674 2/20 0.43
JAK3 P52333 2/20 0.43
PTK2 Q05397 1/20 0.43
DNMT1 P26358 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10165974 0.88 MAPKAPK5 (0.49) MAPKAPK5CCNKCCNA2CDK2CCND3
SCHEMBL1685146 0.87 RAD52 (0.52) ADRA2AADRA2CADRA2BMAPKAPK5MAPKAPK2
SCHEMBL1685214 0.79 MAPKAPK5 (0.60) ADRA2AADRA2CADRA2BMAPKAPK5MAPKAPK2
SCHEMBL13922407 0.78 SMARCA2 (0.53) ADRA2AADRA2CADRA2BMAPKAPK5MAPKAPK2
SCHEMBL1685153 0.77 MAPKAPK5 (0.61) ADRA2AADRA2CADRA2BMAPKAPK5JAK2
SCHEMBL1685141 0.74 SYK (0.45) ADRA2AADRA2CADRA2BMAPKAPK5MAPKAPK2
SCHEMBL1674183 0.74 MAPKAPK5 (0.63) MAPKAPK5EGFR
SCHEMBL1685152 0.73 MAPKAPK5 (0.49) MAPKAPK5MAPKAPK2CCNKCCNA2CDK2
SCHEMBL13922505 0.73 MAPT (0.55) MAPKAPK5
SCHEMBL13922252 0.72 SYK (0.41) MAPKAPK5MAPKAPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120010206-A1 IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES GALAPAGOS N. V. (BE) 2012-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010206-A1 IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES COL2A1, MMP1, COL1A1 ADRA2A 2711/4885ADRA2C 2276/4885ADRA2B 2816/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.